Latest Commercialisation News

Papyrus Australia has made significant strides in Q2 2025, launching its Rapid Prototyping and R&D Facility and successfully trialling new banana fibre-based products, while deepening academic partnerships.

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

Clean TeQ Water Limited reported solid progress across multiple key projects and improved cash receipts in its Q4 FY25 update, underscoring its growing foothold in advanced water treatment and resource recovery.

State Gas Limited has successfully drilled two new wells at its Rolleston West Project, intersecting significant coal seams and initiating production testing, while engaging NSAI for independent reserve certification.

Terragen Holdings reports rapid customer growth for its new dry probiotics, secures a US patent, and posts promising crop trial results, signaling strong momentum in its agricultural biotech offerings.

Invion Limited has secured a $20,000 grant to support its anogenital cancer trial and progressed its skin cancer study with promising early results, while raising approximately $1 million through a Loyalty Option Entitlement Offer.

High-Tech Metals has completed a transformative acquisition of the Mt Fisher and Mt Eureka gold projects, expanding its footprint in Western Australia's Northern Goldfields and setting the stage for aggressive exploration and early production.

Skin Elements Limited advances its proprietary SE Formula biotechnology with ECO-Nurture poised for commercial rollout in 2026, alongside progress in disinfectant and sunscreen product lines.

Provaris Energy has marked significant milestones in Q2 2025 with a key MOU with global shipping leader 'K' LINE and a joint venture formation with Yinson to commercialise proprietary hydrogen and carbon dioxide transport technologies.

Pure Hydrogen reports a second consecutive quarter of positive cash flow, expands its international hydrogen vehicle footprint, and secures a 15-year gas project permit in Queensland.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.